1 reported that flow-mediated vasodilation is enhanced in pregnant women but reduced in preeclampsia. They assessed the vasodilation using biopsies of small arteries. Therefore, their assessment was not in vivo but in vitro study. We assessed flow-mediated vasodilation in pregnant women noninvasively. Noninvasive assessment of flow-mediated vasodilation in nonpregnant subjects was first reported by Celermajer et al, 2 who measured the brachial artery with high-resolution ultrasound (7.5-MHz transducer). We previously reported that with a 30-MHz transducer it is possible to detect endothelial dysfunction more accurately by measuring the radial artery. 3 We examined 60 Japanese women including 20 nonpregnant normotensive healthy women (28.7Ϯ5.0 years old), 18 normal pregnant women (31.3Ϯ5.0 years old, 35.8Ϯ3.1 weeks of pregnancy), and 22 pregnant women with preeclampsia (29.8Ϯ3.8 years old, 36.0Ϯ3.3 weeks of pregnancy). The diagnosis of preeclampsia was made according to the criteria of the Committee on Terminology of the American Collage of Obstetricians and Gynecologists. 4 All 60 subjects were nonsmokers. Images of the radial artery in 60 women were obtained longitudinally with a 30-MHz mechanical linear probe and an SSD-550 system (Aloka, Tokyo, Japan). In each study, we confirmed the clear visualization of the three layers of the vessel wall, including the "m" lines (the interface between media and adventitia) in both near and far walls. When the clear visualization of these layers was confirmed, the probe was fixed with a steel flexible arm. Adequate scans were obtained in all cases. A cuff of 140 mm in width placed on the upper arm was inflated to 30 mm Hg above the systolic pressure for 5 minutes. The radial artery diameter was measured before inflation (baseline) and after deflation of the cuff. Imaging of the artery was performed for 6 minutes after cuff deflation. The radial artery diameter was defined as the distance from the near side of the "m" line in the near wall to the near side of the "m" line in the far wall. Measurements were taken within 1 minute before cuff inflation (baseline) and 30, 60, 90, 120, 180, 240, 300, and 360 seconds after cuff deflation at end diastole. Flow-mediated vasodilation was determined by calculating the change in the radial artery diameter (percent increase for the baseline diameters). Student's t test was used for statistical analysis, and a value of PϽ.01 was considered significant.
Noninvasive Assessment of Flow-Mediated Vasodilation With 30-MHz Transducer in Pregnant Women
To the Editor: Cockell and Poston (April 1997) 1 reported that flow-mediated vasodilation is enhanced in pregnant women but reduced in preeclampsia. They assessed the vasodilation using biopsies of small arteries. Therefore, their assessment was not in vivo but in vitro study. We assessed flow-mediated vasodilation in pregnant women noninvasively. Noninvasive assessment of flow-mediated vasodilation in nonpregnant subjects was first reported by Celermajer et al, 2 who measured the brachial artery with high-resolution ultrasound (7.5-MHz transducer). We previously reported that with a 30-MHz transducer it is possible to detect endothelial dysfunction more accurately by measuring the radial artery. 3 We examined 60 Japanese women including 20 nonpregnant normotensive healthy women (28.7Ϯ5.0 years old), 18 normal pregnant women (31.3Ϯ5.0 years old, 35.8Ϯ3.1 weeks of pregnancy), and 22 pregnant women with preeclampsia (29.8Ϯ3.8 years old, 36.0Ϯ3.3 weeks of pregnancy). The diagnosis of preeclampsia was made according to the criteria of the Committee on Terminology of the American Collage of Obstetricians and Gynecologists. 4 All 60 subjects were nonsmokers. Images of the radial artery in 60 women were obtained longitudinally with a 30-MHz mechanical linear probe and an SSD-550 system (Aloka, Tokyo, Japan). In each study, we confirmed the clear visualization of the three layers of the vessel wall, including the "m" lines (the interface between media and adventitia) in both near and far walls. When the clear visualization of these layers was confirmed, the probe was fixed with a steel flexible arm. Adequate scans were obtained in all cases. A cuff of 140 mm in width placed on the upper arm was inflated to 30 mm Hg above the systolic pressure for 5 minutes. The radial artery diameter was measured before inflation (baseline) and after deflation of the cuff. Imaging of the artery was performed for 6 minutes after cuff deflation. The radial artery diameter was defined as the distance from the near side of the "m" line in the near wall to the near side of the "m" line in the far wall. Measurements were taken within 1 minute before cuff inflation (baseline) and 30, 60, 90, 120, 180, 240, 300, and 360 seconds after cuff deflation at end diastole. Flow-mediated vasodilation was determined by calculating the change in the radial artery diameter (percent increase for the baseline diameters). Student's t test was used for statistical analysis, and a value of PϽ.01 was considered significant.
Baseline radial artery diameters in nonpregnant women, normal pregnant women, and preeclamptic women were 2.26Ϯ0.42, 2.41Ϯ0.38, and 2.22Ϯ0.35 mm, respectively. No significant differences were seen among these groups. Maximum dilation was obtained 1 minute after cuff deflation. The percent increases of radial artery diameter during reactive hyperemia in nonpregnant women, normal pregnant women, and preeclamptic women were 11.8Ϯ3.6%, 18.9Ϯ3.4%, and 7.9Ϯ3.0%, respectively. In normal pregnant women, vasodilation was significantly greater than that in nonpregnant women (PϽ.001). Vasodilation in preeclamptic women was significantly less than that in normal pregnant women (PϽ.001) or nonpregnant women (PϽ.001).
Our results indicate that peripheral vascular endothelial function in pregnant women was improved, but in preeclamptic women endothelial function was impaired. Our conclusions were in accordance with the findings of Cockell and Poston. Using our method, we can asses the endothelial function in pregnant women noninvasively. Because Cockell and Poston used biopsies obtained at cesarean section, their assessment was limited to subjects at or near term, but our method is applicable to subjects even in early pregnancy. Further work is in progress to evaluate the usefulness of our method as a predictor of preeclampsia.
Atsushi Yoshida Shinji Nakao Hisaaki Kobayashi Mitsunao Kobayashi Department of Perinatal and Maternal Medicine
National Defense Medical College Saitama, Japan
Response
We read with interest the letter of Yoshida et al describing a study of the reactive hyperemic response in radial arteries of nonpregnant and pregnant women and of patients with preeclampsia. Using ultrasonography, the authors have shown blunted dilatation after cuff inflation on the upper arm in women with preeclampsia when compared with findings in normal pregnant women. These data would appear to confirm our in vitro findings described in Hypertension, 1 in which we showed blunted endothelium-dependent, nitric oxide-mediated dilatation to shear stress in small arteries obtained during caesarean section from women with preeclampsia. However, some degree of caution should be applied when ascribing endothelium dependence to the abnormal dilatory response in the radial arteries, since vasodilation induced by hyperemia of the upper arm will undoubtedly lead to endothelium-independent elements of relaxation unrelated to increased flow per se 2 in the lower arm. Previous studies have circumvented this problem by applying the cuff to the lower arm, thus evoking an increase in shear stress in the upper arm but precluding any influence of locally acting metabolites. 3 Nonetheless, Yoshida et al have shown clearly that vasodilator responses are significantly increased in pregnant women compared with nonpregnant and are blunted in women with preeclampsia. Together with our observations in resistancesized arteries in vitro, these data add further strength to the hypothesis that impairment of vasodilatory responses may contribute to elevation of the blood pressure in women with preeclampsia.
Is Plasma Ac-SDKP Level a Reliable Marker of Chronic Angiotensin-Converting Enzyme
Inhibition in Hypertensive Patients?
To the Editor:
In a recent article, Azizi et al 1 suggested that the plasma levels of N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) could be a reliable marker of chronic angiotensin-converting enzyme (ACE) inhibition in hypertensive patients treated by ACE inhibitors (ACEI). We were concerned by their results because some of them contradict while others agree with several of our very recent findings. The tetrapeptide Ac-SDKP (molecular weight, 487 D), a physiological inhibitor of the proliferation of hematopoietic stem cells 2 that is present in normal plasma at stable concentrations, 3 is degraded by ACE both in vitro and in vivo. 4, 5 In a previous study in healthy volunteers, Azizi et al 6 showed that a single oral dose of captopril, an ACEI, transiently increases the plasma levels of Ac-SDKP. In a recent study, we showed that 15-day treatment of healthy volunteers by another ACEI (enalapril) permanently increases the plasma concentrations and daily urinary elimination of Ac-SDKP by approximately 4-fold and modifies the levels of blood hematopoietic progenitors. 7 In the Hypertension article cited above, Azizi et al 1 showed that chronic treatment of hypertensive patients by any type of ACEI permanently increased plasma Ac-SDKP levels by 5 times compared with levels in non-ACEI hypertensive patients or healthy control subjects. They thus suggested that plasma Ac-SDKP levels could be a better marker of the compliance of hypertensive patients to their chronic ACEI treatment than the currently used markers of ACE activity, such as plasma renin or angiotensin II/angiotensin I ratio. Azizi et al also found evidence that the plasma Ac-SDKP levels correlated to the creatinine clearance in the ACEI-treated group but not in the non-ACEI-treated group of patients. These data led them to suggest that "it is the accumulation of the ACE inhibitor in plasma associated with renal failure and not renal failure per se that is responsible for the higher levels of the peptide when the renal clearance of ACE inhibitors is impaired." However, they mentioned that this point warranted further investigation because "only very few non-ACEI patients had severe renal insufficiency."
The results of an investigation that we recently performed in 56 uremic patients (21 being treated with an ACEI) and 51 healthy control subjects contradict this hypothesis. The creatinine clearance of these chronic renal failure (CRF) patients (calculated with the Crockroft formula) ranged from 4 to 82 mL/min (median, 18.65 mL/min). The plasma concentrations of Ac-SDKP were significantly higher (PϽ0.01) in CRF patients without ACEI (range, 0.83 to 11.69 pmol/mL; median, 2.74 pmol/mL) than in controls (range, 0.4 to 6 pmol/mL; median, 1.5 pmol/mL). Plasma Ac-SDKP was still much higher in CRF patients with ACEI (range, 1.37 to 40.2 pmol/mL; median, 12.15 pmol/mL). We also showed that in CRF patients without ACEI, the plasma levels of Ac-SDKP inversely correlated with the creatinine clearance (rϭϪ0.57, PϽ0.01). Conversely, unlike Azizi et al, 1 we did not find a similar correlation in ACEI patients. Moreover, some of our ACEI-treated CRF patients did not have higher levels of plasma Ac-SDKP than non-ACEItreated CRF patients or even than healthy control subjects. Therefore, at least in our study, Ac-SDKP cannot discriminate patients taking from those not taking an ACEI. This could be explained by the fact that our CRF patients, with different degrees of renal insufficiency, received different types and dosages of ACEI. Together with those of our previous study, 7 our present data confirm that the renal elimination of Ac-SDKP plays a major role in the mechanisms regulating its plasma levels, as could be expected from the low molecular weight (487 D) of Ac-SDKP. These data contradict the hypothesis of Azizi et al mentioned above.
In consideration of the well-known direct effect of Ac-SDKP on the cycling of hematopoietic progenitors, 8 Azizi et al also suggest that chronic accumulation of Ac-SDKP in plasma during ACEI treatment could participate in the alterations of hematopoiesis observed in CRF and renal transplant patients. This hypothesis is supported by our recent results showing a decrease of blood committed hematopoietic progenitors (BFU-E and CFU-GM), contrasting with an increase of early progenitors (CFU-mix) in ACEItreated healthy controls. 7 In addition, it is interesting that Mrug et al 9 very recently showed that angiotensin II increases the in vitro proliferation of erythroid progenitors. Therefore, a significant increase in Ac-SDKP (which inhibits the proliferation of primitive hematopoietic progenitors) together with a decrease of angiotensin II (which activates late erythropoietic progenitors) in the plasma of ACEI-treated patients could reduce the erythroid commitment of primitive hematopoietic progenitors, as well as the proliferation and differentiation of later committed erythroid precursors in CRF patients. These aspects of potential therapeutic interest warrant further investigations.
Yannick Le Meur Jean-Claude Aldigier Service de Néphrologie Centre Hospitalier Universitaire
Limoges, France
Vincent Praloran Laboratoire d'Hématologie Expérimentale Faculté de Médecine Limoges, France

Response
We are very pleased that Le Meur et al read in detail our article showing that plasma Ac-SDKP concentration is consistently high when ACE is chronically inhibited 1 and that they presented their own recent results on hematopoietic cells. 2 Both results show the importance of the ACEI-induced increase in endogenous Ac-SDKP levels in plasma 1, 3 and possibly also in tissues, not only in accounting for the hematologic effect of ACEIs (in particular for conditions such as CRF 4 ) but also as a new therapeutic strategy to prevent hematologic toxicity of anticancer chemotherapy. 5, 6 The discussion on the absence or presence of a relationship between plasma Ac-SDKP levels and creatinine clearance may not be useful and perhaps may be even misleading. Both studies found (1) lower Ac-SDKP levels in patients with normal renal function than in patients with renal dysfunction and (2) a further increase in plasma Ac-SDKP levels in ACEI-treated patients with CRF. Therefore, the data of Le Meur et al agree with our results more than they contradict them. The presence or absence of a correlation may be due to multiple minor problems: selection of different patients and of different types and doses of ACEIs, aberrant values, inappropriate statistical tests, and above all, low power of both studies.
Our last point of concern is that plasma Ac-SDKP determination did not detect chronic ACE inhibition in some of their patients with CRF, the number of whom was not reported. This is in contradiction to the pharmacokinetics of the exogenous peptide, 7 the metabolism of the peptide (for which no enzymatic pathway other than that involving ACE exists 8 ), the pharmacokinetics of all ACEIs that accumulate in plasma and tissues during renal failure, 9 and their own data showing urinary elimination of the peptide. 2 Other than a possible problem in the timing of the blood sampling, which was not reported in the study of Le Meur et al (blood taken after dialysis or more than 24 hours after intake of a low dose of an ACEI in a patient with a mild degree of renal failure), the only other possible explanation is lack of compliance with the ACEI treatment by the patients. This emphasizes that the determination of plasma Ac-SDKP is a very sensitive method for the detection of an ACEI in the body, which can be used by physicians to check their patients' compliance with a simple measurement.
